Maintenance outage: This site will be inaccessible from late evening Mar 7th thru Mar 8th. This is for scheduled technology upgrades by our global hosting service that are affecting numerous websites and online journals. Note that our submission site is still accessible during this period and processing of new submissions will not be affected.
  Follow this preprint

Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label randomized clinical trial (DOXYCOV)

Eugene Sobngwi, Sylvain Zemsi, Magellan Guewo-Fokeng, Jean-Claude Katte, Charles Kounfack, Liliane Mfeukeu-Kuate, Armel Zemsi, Yves Wasnyo, Antoinette Assiga Ntsama, Arnaud Ndi-Manga, Joelle Sobngwi-Tambekou, William Ngatchou, Charlotte Moussi Omgba, Jean Claude Mbanya, Pierre Ongolo Zogo, Pierre Joseph Fouda
doi: https://doi.org/10.1101/2021.07.25.21260838
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Data Availability

Data availability is subject to prior approval by the National Ethics Committee of Cameroon and the Minister of Public Health

Back to top
Posted July 29, 2021.
Download PDF
Print/Save Options
Download PDFFull Text & In-line FiguresXML
Data/Code
Email
Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label randomized clinical trial (DOXYCOV)
Eugene Sobngwi, Sylvain Zemsi, Magellan Guewo-Fokeng, Jean-Claude Katte, Charles Kounfack, Liliane Mfeukeu-Kuate, Armel Zemsi, Yves Wasnyo, Antoinette Assiga Ntsama, Arnaud Ndi-Manga, Joelle Sobngwi-Tambekou, William Ngatchou, Charlotte Moussi Omgba, Jean Claude Mbanya, Pierre Ongolo Zogo, Pierre Joseph Fouda
medRxiv 2021.07.25.21260838; doi: https://doi.org/10.1101/2021.07.25.21260838
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area

Reviews and Context

0

Comment

0

TRIP Peer Reviews

0

Community Reviews

0

Automated Services

0

Blogs/Media

0

Author Videos

You can now receive automatic notifications when a preprint is revised, withdrawn, commented on, peer reviewed, or published in a journal. Select the events you would like to follow below and click "Submit". To see all of the preprints you are currently following, please go to the medRxiv Alerts Page.

Sign In to Follow this Preprint

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.